Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Key Inclusion Criteria: * Written informed consent or assent * Subject has completed study TR02-108, and has been compliant with the study protocol * Women of childbearing potential must agree to use reliable methods of contraception for the duration of the study Key Exclusion Criteria: * Subject met any of the listed criteria for study drug discontinuation in protocol TR02-108. * Abnormal laboratory assessments including LFT (≥ 3× upper limit of normal \[ULN\]), serum creatinine (\> 2× ULN) and absolute neutrophil count \[ANC\] (\< 1000). * Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements. * History of alcohol, medication or illicit drug abuse within the 6 months prior to consent. * Smoking tobacco or any substance within 6 months prior to consent or anticipated inability to refrain from smoking throughout the study